Last updated on February 2018

ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Na ve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)


Brief description of study

The purpose of this study is to assess ALXN1210 compared to eculizumab in adult patients with PNH who have not previously used a complement inhibitor.

Clinical Study Identifier: NCT02946463

Contact Investigators or Research Sites near you

Start Over

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Whittier, CA United States

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Toronto, Canada

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Bogotá, Colombia

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Cali, Colombia

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Medellín, Colombia

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Tallinn, Estonia

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Poitiers, France

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Montpellier, France

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Paris, France

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Essen, Germany

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Ulm, Germany

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Napoli, Italy

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Ogaki, Japan

Alexion Pharmaceuticals, Email for Complete ...

ClinicalTrial Site
Kanazawa, Japan

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Koshigaya, Japan

Alexion Pharmaceuticals, Email for Complete ...

Clinical Trial Site
Shinjuku, Japan